Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | RAD52 | P43351 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8930316 | 0.74 | ABCB1 (0.44) | KMT2ATP53MAPTMEN1 | |
| SCHEMBL14473078 | 0.74 | POLB (0.55) | POLBKMT2ALMNAGLAGAA | |
| SCHEMBL30815826 | 0.72 | LMNA (0.61) | POLBKMT2ALMNAGLAGAA | |
| SCHEMBL3103845 | 0.72 | LMNA (0.61) | POLBKMT2ALMNAGLAGAA | |
| Hydrochloric Acid SCHEMBL3107661 | 0.72 | LMNA (0.64) | POLBKMT2ALMNAGLAGAA | |
| SCHEMBL14563026 | 0.71 | — | — | |
| SCHEMBL14069034 | 0.70 | ENPP1 (0.43) | POLBKMT2ALMNAGLAGAA | |
| SCHEMBL1512508 | 0.70 | ADRA1D (0.53) | — | |
| SCHEMBL2847409 | 0.69 | KDM4E (0.69) | KMT2ALMNAGLAGAATP53 | |
| Hydrochloric Acid SCHEMBL1690850 | 0.69 | KDM4E (0.68) | KMT2ALMNAGLAGAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069562-A1 | Process for the preparation of alfuzosin | AUROBINDO PHARMA LTD (IN) | 2009-03-12 | — | — | US | disclosed |
| WO-2007074364-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN | AUROBINDO PHARMA LIMITED (IN) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069562-A1 | Process for the preparation of alfuzosin | QDPR, OPRD1, OPRK1 | POLB 4334/4885KMT2A 926/4885LMNA 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.